Esperion Reports Results of Bempedoic Acid in P-III Study 2 or 1002-047 for Patients with ASCVD or HeFH
Shots:
- The P-III (1002-047) study involve assessing of Bempedoic Acid (180 mg qd) vs PBO in 779 patients in ratio 2:1 with ASCVD OR HeFH for 52 wks.
- P-III Study 2 or 1002-047 results: LDL-C lowering 18%; reduction in High-Sensitivity C-reactive protein (hsCRP) 19%; Reduction in Hemoglobin A1c (HbA1c) 0.21%; MACE events 3/4/5 component (2.7%- 5.7%- 6.1% vs 4.7%- 7.8%- 8.2%); safe and well tolerated
- Bempedoic Acid PO is a novel qd ACLi helps in lowering LDL-C. In 2016- Esperion initiated onset of global P-III trial with five studies in 4000 patients evaluating bempedoic acid and bempedoic acid + ezetimibe
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
